Evidence map›Paper›PMID 37278031›Full record

Trial reportDeutsches Arzteblatt international2023

A Complex Intervention to Prevent Medication-Related Hospital Admissions.

Antje Neubert, Irmgard Toni, Jochem König, Dorothée Malonga Makosi, Philipp Mildenberger, Marcel Romanos, Astrid Bertsche, Thilo Bertsche, Peter Dahlem, Karin Egberts and 19 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Deutsches Arzteblatt international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The epidemiology of drug-related hospital admissions in paediatrics - a systematic review.Archives of public health = Archives belges de sante publique · 2024
    Pooled it
  2. Article
  3. [Recording medication errors in Germany-a workshop report].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026
    Article
  4. Article
  5. Pharmacotherapy for Children and Adolescents.Deutsches Arzteblatt international · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Antje NeubertDepartment of Pediatric and Adolescent Medicine, University Hospital Erlangen
Irmgard ToniDepartment of Pediatric and Adolescent Medicine, University Hospital Erlangen
Jochem KönigInstitute for Medical Biometry, Epidemiology and Information Technology, University Medicine of the Johannes Gutenberg University of Mainz.
Dorothée Malonga MakosiInstitute for Medical Biometry, Epidemiology and Information Technology, University Medicine of the Johannes Gutenberg University of Mainz.
Philipp MildenbergerInstitute for Medical Biometry, Epidemiology and Information Technology, University Medicine of the Johannes Gutenberg University of Mainz.
Marcel RomanosDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg
Astrid BertscheUniversity and University Hospital of Leipzig, Faculty of Medicine, Center for Drug Safety (ZAMS)
Thilo BertscheUniversity and University Hospital of Leipzig, Faculty of Medicine, Center for Drug Safety (ZAMS)
Peter DahlemREGIOMED Hospital Coburg, Department for Pediatric and Adolescent Medicine
Karin EgbertsDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg
Bernhard ErdlenbruchUniversity Department for Pediatric and Adolescent Medicine, Johannes Wesling Hospital Minden, Ruhr University of Bochum
Stefanie FeketeDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg
Ulrike HaugLeibniz Institute for Prevention Research and Epidemiology – BIPS
Gerd HorneffAsklepios Children’s Hospital Saint Augustin
Axel HüblerHospital of Chemnitz, Department for Pediatric and Adolescent Medicine
Wieland KiessUniversity Hospital of Leipzig, Clinic and Outpatient Clinic for Pediatric and Adolescent Medicine
Martina P NeiningerUniversity and University Hospital of Leipzig, Faculty of Medicine, Center for Drug Safety (ZAMS)
Tim NiehuesCenter for Pediatric and Adolescent Medicine, Helios Hospital Krefeld
Bernhardt SachsFederal Institute for Drugs and Medical Devices (BfArM), Research Department
Karl-Florian SchettlerSt. Marien Children’s Hospital, Landshut
Filippa SchreeckDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert Bosch Society for Medical Research Stuttgart
Tim SteimleTK Health Insurance Fund, Hamburg
Tobias WenzlUniversity Hospital of Aachen, Department for Pediatric and Adolescent Medicine
Stefan WirthCenter for Pediatric and Adolescent Medicine, Helios University Hospital Wuppertal
Fred ZeppUniversity Medical Center of the Johannes Gutenberg University of Mainz, Clinic and Polyclinic of Pediatrics and Adolescent Medicine
Matthias SchwabDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert Bosch Society for Medical Research Stuttgart
Michael S UrschitzInstitute for Medical Biometry, Epidemiology and Information Technology, University Medicine of the Johannes Gutenberg University of Mainz.
Wolfgang RascherDepartment of Pediatric and Adolescent Medicine, University Hospital Erlangen
KiDSafe Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChildren are often treated off-label and are at a disadvantage in pharmacotherapy. The aim of this study was to implement and evaluate a quality assurance measure (PaedPharm) for pediatric pharmacotherapy whose purpose is to reduce medication-related hospitalizations among children and adolescents.

methodsPaedPharm consisted of the digital pediatric drug information system PaedAMIS, pediatric pharmaceutical quality circles (PaedZirk), and an adverse drug event (ADE) reporting system (PaedReport). The intervention was implemented in a cluster-randomized trial (DRKS 00013924) in 12 regions, with a pediatric and adolescent medicine clinic in each and a total of 152 surrounding private practitioners, in 6 sequences over 8 quarters. In addition to the proportion of ADE-related hospital admissions (primary endpoint), comprehensive process evaluation included other endpoints such as coverage, user acceptance, and relevance to practice.

results41 829 inpatient admissions were recorded, of which 5101 were patients of physicians who participated in our study. 4.1% of admissions were ADE-related under control conditions, and 3.1% under intervention conditions (95% CI: [2.3; 5.9] and [1.8; 4.5], respectively). A model-based comparison yielded an intervention effect of 0.73 (population-based odds ratio; [0.39; 1.37]; p = 0.33). PaedAMIS achieved moderate user acceptance and PaedZirk achieved high user acceptance.

conclusionThe introduction of PaedPharm was associated with a decrease in medication-related hospitalizations that did not reach statistical significance. The process evaluation revealed broad acceptance of the intervention in outpatient pediatrics and adolescent medicine.

Indexed as

Drug-Related Side Effects and Adverse ReactionsHospitalizationAdolescentChildHospitalsHumans

Identifiers

PMID37278031
PMCPMC10478767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.